Meeder Asset Management’s Matinas BioPharma MTNB Stock Holding History

Meeder Asset Management’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3	Closed	-$969	–	1635
2018 Q2	$969	Hold	3	–	–	﹤0.01%	1496
2018 Q1	$1K	Hold	3	–	–	﹤0.01%	1461
2017 Q4	$2K	Buy	3 +1	+50%	+$965	﹤0.01%	1496
2017 Q3	$2K	Buy	2 +1	+100%	+$1K	﹤0.01%	1467
2017 Q2	$1K	Buy	+1	New	+$2.01K	﹤0.01%	1528

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Element Capital Management New York $3.2B AUM 29.54% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

KJHP

K.J. Harrison & Partners Toronto, Ontario, Canada $706M AUM 48.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Meeder Asset Management's MTNB Position: Q3 2018 in Review

Meeder Asset Management sold out of Matinas BioPharma (MTNB) in Q3 2018, closing a stake of 3 shares — an estimated $969 sold.

Meeder Asset Management first reported a position in MTNB in Q2 2017 and held it in 5 quarters. The position peaked at $2K in Q4 2017. 30 funds tracked by Wall St. Rank hold MTNB as of Q3 2018.

Meeder Asset Management reported no remaining Matinas BioPharma position as of Q3 2018 after selling out during the quarter.
Meeder Asset Management sold 3 Matinas BioPharma shares in Q3 2018, an estimated $969.
Meeder Asset Management first reported a position in Matinas BioPharma in Q2 2017 and held it in 5 quarters.
Meeder Asset Management's Matinas BioPharma position peaked at $2K in Q4 2017.
30 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2018.

Based on Meeder Asset Management's 13F filing for Q3 2018, filed 2 Nov 2018.